Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kathleen Colson"'
Autor:
Constantine S. Mitsiades, Mary McKenney, Teru Hideshima, Katherine Redman, Robert L. Schlossman, Paul G. Richardson, Kathleen Colson, Diane Warren, Irene M. Ghobrial, Laura E. Lunde, Nikhil C. Munshi, Kimberly Noonan, Deborah Doss, Kenneth C. Anderson, Jacob P. Laubach
Publikováno v:
European Journal of Haematology. 88:446-449
We present the case of a woman with relapsed multiple myeloma (MM) who received combination lenalidomide and bortezomib therapy for 90 cycles followed by continuous lenalidomide monotherapy and has completed over 100 cycles of treatment to date. The
Autor:
Dixie-Lee Esseltine, Melissa Alsina, Irene M. Ghobrial, Kathleen Colson, Paul G. Richardson, John Feather, Nikhil C. Munshi, Laura E. Lunde, Robert L. Schlossman, Sagar Lonial, Kenneth C. Anderson, Robert Knight, Andrzej Jakubowiak, Sundar Jagannath, Teru Hideshima, David H. Vesole, Constantine S. Mitsiades, Mary McKenney, Amitabha Mazumder, Noopur Raje
Publikováno v:
Blood. 116:3049-3049
Abstract 3049 Background: Single-agent bortezomib (btz) and lenalidomide (len)-dexamethasone (dex) are associated with higher rates of response and improved survival vs dex alone in relapsed MM, and both are approved for treatment of MM pts with ≥1
Autor:
Constantine S. Mitsiades, Kenneth C. Anderson, Kara Kosakowski, Sundar Jagannath, Amitabha Mazumder, Melissa Alsina, Sagar Lonial, Laura E. Lunde, Kathleen Colson, Nikhil C. Munshi, Irene M. Ghobrial, Noopur Raje, Sarah Kennedy, Teru Hideshima, Dixie-Lee Esseltine, Andrzej Jakubowiak, Robert Knight, David H. Vesole, Paul G. Richardson, Mary McKenney
Publikováno v:
Blood. 112:1742-1742
Background: Bortezomib (VELCADE®, Bz) is approved for the treatment of multiple myeloma (MM). Lenalidomide (Revlimid®, Len) plus dexamethasone (Dex) is approved for the treatment of relapsed MM pts following ≥ 1 prior therapy. In a phase 1 study,
Autor:
Cliona McAlister, Deborah Doss, Hani Hassoun, Sagar Lonial, Barbara Stoklas, Patrick Y. Wen, Andrea Freeman, Svetlana Gorelik, Paul G. Richardson, Kathleen Colson, Anthony A. Amato, Karen Hande, Dixie Lee Esseltine, Denise Collins, Kenneth C. Anderson, Mary McKenney, David J. Kuter, Diane Warren, Nikhil C. Munshi, Laura E. Lunde, Asher A. Chanan-Khan, Hannah Briemberg, Robert L. Schlossman, Anne Louise Oaklander, Alexandra Koryzna
Publikováno v:
Blood. 104:336-336
Introduction: Bortezomib, a first in class proteasome inhibitor, has become a standard of care in the treatment of relapsed and refractory MM. A recent randomized Phase 3 trial showed an improvement in time to progression (TTP) and overall survival r
Autor:
Anna Stepanek, Nikhil C. Munshi, Paul G. Richardson, Laura E. Lunde, Reggie Michelle, Nicholas Mitsiades, Robert L. Schlossman, Deborah Doss, Svetlana Gorelik, Constantine S. Mitsiades, Stephen Hayes, Andrea Freeman, Victoria M. Richon, Kathleen Colson, Diane Warren, Mary McKenney, Keith Doucet, Judi Chiao, Kenneth C. Anderson, Karyn Dinand, Karen Hande
Publikováno v:
Blood. 104:1503-1503
Introduction: Histone deacetylases (HDACs) affect cell growth at the transcriptional level by regulating the acetylation status of nucleosomal histones, and HDAC inhibition induces differentiation and/or apoptosis in transformed cells. We have recent